Sadhana Nitro Chem: consolidated loss narrows to ₹0.55 Cr in Q1 FY27 as margins expand

Sadhana Nitro Chem's consolidated Q1 FY27 (quarter ended June 30, 2026) net loss narrowed to ₹0.55 Cr from ₹2.12 Cr a year earlier, even as revenue from operations slipped 3.1% YoY to ₹27.22 Cr from ₹28.10 Cr. The improvement is margin-led rather than volume-led: operating margin (EBITDA/revenue) expanded to ~8.5% from ~6.9% in Q1 FY26, and net margin (PAT/total income) improved to -1.8% from -6.5%, aided by lower finance costs (₹3.19 Cr vs ₹4.01 Cr YoY). Standalone (parent-only) results were similar — a ₹0.40 Cr loss on ₹26.18 Cr revenue — with the gap to consolidated explained by Belgian subsidiary Anuchem B.V.B.A., which added ₹5.62 Cr of revenue and a ₹0.12 Cr pre-tax loss to the group. Sequentially both revenue and profit look sharply better than the March 2026 quarter (₹9.11 Cr revenue, ₹33.62 Cr loss), but auditors flag Q4 FY26 as a balancing/plug figure, so that comparison is not a clean momentum read. The company carries no formal guidance or prior concall commentary on record, and no analyst/street estimates could be identified for this print, so both the guidance and street checks are unknown rather than a stated beat or miss. Management's release carries no commentary beyond the results and board outcomes. Two corporate actions landed alongside the results: the board approved a ₹13.9 Cr preferential allotment of 6.75 Cr shares at ₹2.06 apiece the same day, taking paid-up capital from ₹296.47 Cr to ₹303.22 Cr, and separately confirmed no deviation in utilization of rights-issue proceeds — both balance-sheet items, not P&L drivers this quarter. The ₹108 Cr speciality-chemical export deal announced May 28, 2026 has not yet shown up as revenue growth here (revenue is still down YoY), suggesting execution is still ahead of this print rather than in it. EPS is effectively nil (~₹0.00) on both bases given the roughly 296 Cr-share base, and neither period carried exceptional items.